- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04044781
A Phase 1, Open-Label, PET Study of T2310 & BPN14770
A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of BPN14770
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Willing and able to provide written informed consent.
- 2. Subjectively healthy
- 3. Between 18 and 75 years, inclusive, but preference will be given to subjects who are less than 55 years old.
- 4. The subject weighs at least 45 kg and has a body mass index between 18.0 and 32 kg/m2.
- 5. Subjects should be willing to observe the following contraception requirements from Screening until 90 days after the final follow-up visit: Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to dosing BPN14770 or use at least one barrier method of birth control). Female subjects: Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to dosing of BPN14770), at least two years post-menopausal, or willing to use one barrier plus a hormonal contraceptive method of contraception from initial screening until one month after taking the last dose of study drug
Exclusion Criteria:
- 1. Known history or evidence of a clinically significant medical condition, disorder, or disease that, in the opinion of the investigator, would pose a risk to subject safety, proper completion of the procedures, or the integrity of the study.
- 2. Clinical laboratory studies suggestive of a medically meaningful disease or condition that, in the opinion of the investigator, could pose a risk to subject safety, proper completion of the procedures, or the integrity of the study.
- 3. Contraindication to MRI based on the standard MRI screening questionnaire at CBIC. Contraindications include ferromagnetic foreign bodies (e.g., shrapnel, ferromagnetic sheet metal fragments in the orbital area), certain implanted medical devices (e.g., older aneurysm clips, cardiac pacemakers), or claustrophobia.
- 4. Unexpected findings on screening MRI that are indicative of an occult brain disease, or will potentially compromise subject safety or the scientific integrity of the study data.
- 5. Previous exposure to ionizing radiation for research purposes, such that, in combination with the exposure from this study, their exposure to research associated radiation will be >50 mSv/year for the previous year.
- 6. Subjects who are atopic, or have a known hypersensitivity to any component of the formulation of BPN14770 or to [11C]T2310 PET scan.
- 7. History of substance dependence, or current use of drugs of abuse.
8. History of regular weekly alcohol consumption >21 units for male subjects or >14units for female subjects or unable to abstain from alcohol from 24 hours prior to Screening visits and 24 hours prior to Period 2 Day (-1) until discharge at the end of Period 2.
9. Female subjects who are pregnant or lactating. 10. Use of any prescription drugs within 14 days or 5 half-lives (whichever is longer) before the first dose of an investigational product, unless in the opinion of the investigator (or delegate) and the Sponsor's Medical Monitor the medication will not interfere with the study procedures, the pharmacokinetics of either the radiopharmaceutical or the investigational drug product, or compromise subject safety. An example of potentially acceptable drug use might be beta blockers in eye drops for glaucoma.
- 11. Use of any non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) before the first dose of the study agents, unless in the opinion of the Investigator (or delegate) and the Sponsor's Medical Monitor the medication will not interfere with the study procedures, the pharmacokinetics of either the radiopharmaceutical or the investigational drug product, or compromise subject safety.
- 12. Subjects who have received an investigational drug as part in another study within the last 30 days or 5 half-lives of the investigational drug for the previous study (whichever is longer).
- 13. History of acquired immunodeficiency syndrome (AIDS).
- 14. Poor peripheral venous access.
- 15. Donation of ≥450 mL blood or loss of blood during surgery within 30 days prior to Day 1.
- 16. Plasma donation >100 mL within 7 days prior to Day 1.
- 17. In the Investigator's judgement it is better for the subject not to be enrolled in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Test Group
Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers.
Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
|
Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 1-8 Days
|
To assess the safety and tolerability of [11C]T2310 when administered alone and when co-administered with BPN14770
|
1-8 Days
|
Plasma Concentration
Time Frame: 24 Hours
|
To determine relationships between plasma concentrations of BPN14770 and the total volume of distribution of T2310 as a proxy for brain PDE4D occupancy by BPN14770 following single oral dosing regimens of BPN14770 over a 24 hour time
|
24 Hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul D Mozley, MD, Weill Cornell College of Medicine
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- T2310-PET-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Determine Brain Target Occupancy of BPN14770
-
Par Pharmaceutical, Inc.SFBC Ft. Myers, IncCompletedTo Determine the Bioavailability of TranylcypromineUnited States
-
Fundació Institut de Recerca de l'Hospital de la...CompletedTo Determine the Efficacy of Two Liquid Oxygen DeviceSpain
-
Kai SchoenhageCompletedDetermine Validity of Concept of Using Hemoglobin Dilution to Assess/Measure Blood Volume.United States
-
Texas Woman's UniversityCompletedTo Determine the Psychometric Properties of the Short Child Occupational ProfileUnited States
-
Rajavithi HospitalCompletedTo Determine Whether ERAS Can Reduce Length of Stay in Pregnant Women After Cesarean SectionThailand
-
Dalhousie UniversityCompletedTo Determine the Change in Demonstrated Anesthesia Non-technical Skills After Delivery of the VAST CourseRwanda
-
Yeditepe UniversityRecruitingTo Determine the Levels of miRNA1 and miRNA133a Before and After ExerciseTurkey
-
Texas Woman's UniversityCompletedCerebral Palsy | To Determine Efficacy of the HeadpodUnited States
-
Galderma R&DCompletedDetermine Sensitivity of Skin to Cetaphil Daily Advance Ultra Hydrating Lotion
-
GE HealthcareLaboratory Corporation of AmericaCompletedStudy to Determine Dosage of OPTISON in Children Between ≥9 and <18 Years of Age Weighing ≥20 kgUnited States
Clinical Trials on BPN14770, T2310
-
Tetra Discovery PartnersUnknownAlzheimer's DiseaseUnited States
-
Tetra Discovery PartnersCompletedAlzheimer's DiseaseUnited States
-
Tetra Discovery PartnersCompletedAlzheimer's DiseaseUnited States
-
National Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Tetra Discovery PartnersEnrolling by invitationFragile X SyndromeUnited States
-
Tetra Discovery PartnersRecruitingFragile X SyndromeUnited States
-
Tetra Discovery PartnersCompletedFragile X Syndrome | Fra(X) Syndrome | FXSUnited States
-
Tetra Discovery PartnersRecruitingFragile X SyndromeUnited States
-
Tetra Discovery PartnersCompletedAlzheimer DiseaseUnited States